SEC Form SC 13G filed by Biomerica Inc.

2/9/24 3:06:57 PM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $BMRA alert in real time by email

SC 13G 1 bmra224.txt SCHEDULE 13G Amendment No. Name of Issuer: Biomerica, Inc. Title of Class of Securities: Common Stock CUSIP Number: 09061H307 Item 1: Reporting Person: Wasatch Advisors LP 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 953,264 Item 6: Shared Voting Power: 0 Item 7: Sole Dispositive Power: 953,264 Item 8: Shared Dispositive Power: 0 Item 9: Aggregate Amount Owned: 953,264 Item 10: Check Box If Aggregate Amount Excludes Certain Shares: N/A Item 11: Percent of Class Owned: 5.7% Item 12: Type of Reporting Person: IA Item 1(a): Name of Issuer: Biomerica, Inc. Item l(b): Address of Issuer: 17571 Von Karman Avenue, Irvine, CA 92614 Item 2(a): Name of Person Filing: Wasatch Advisors LP Item 2(b): Address: 505 Wakara Way, Salt Lake City, UT 84108 Item 2(c): Citizenship: Not Applicable Item 2(d): Title of Class of Securities: Common Stock Item 2(e): CUSIP Number: 09061H307 Item 3(e): Investment Adviser registered under section 203 of the Investment Advisers Act of 1940 Item 4(a): Amount Owned: 953,264 Item 4(b): Percent of Class Owned: 5.7% Item 4(c)(i): Sole Voting Power: 953,264 Item 4(c)(ii): Shared Voting Power: 0 Item 4(c)(iii): Sole Dispositive Power: 953,264 Item 4(c)(iv): Shared Dispositive Power: 0 Item 5: Check Box If Ownership Is 5% or Less of Class: [ ] Item 6. Ownership of More Than 5% on Behalf of Another Person: N/A Item 7: Identification of Subsidiary: Not Applicable Item 8: Identification of Members of Group: Not Applicable Item 9: Notice of Dissolution of Group: Not Applicable Item 10: Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct as of December 31, 2023. Date: 02/09/24 Signature: /s/JB Taylor Name/Title: JB Taylor/CEO

Get the next $BMRA alert in real time by email

SEC Form SC 13G filed by Biomerica Inc.

2/9/24 3:06:57 PM ET

$BMRA

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $BMRA alert in real time by email

SEC Form SC 13G filed by Biomerica Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$BMRA

SEC Form SC 13G filed by Biomerica Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$BMRA

$BMRA
SEC Filings

SEC Form 10-K filed by Biomerica Inc.

Biomerica Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

Biomerica Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

$BMRA
Press Releases

$BMRA
Insider Trading

Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes

United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Kidney Test for Home Use

Biomerica Reports Fiscal 2025 Year End Results

New insider Chin Eric claimed ownership of 10,000 units of Restricted Stock (SEC Form 3)

Director Emerson Jane was granted 85,000 shares, increasing direct ownership by 120% to 156,000 units (SEC Form 4)

Director Coste Catherine was granted 85,000 shares, increasing direct ownership by 194% to 128,790 units (SEC Form 4)

$BMRA
Leadership Updates

Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica's Team as Chief Commercial Officer

Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair

Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board

$BMRA
Financials

Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022

$BMRA
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Biomerica Inc.

SEC Form SC 13G/A filed by Biomerica Inc. (Amendment)